Q-omics provides the consensus-scored FADS3 profile across patient tissues and cancer cell-line models. FADS3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FADS3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FADS3 RNA expression shows 17,788 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where FADS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FADS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FADS3 survival associations across molecular data types. FADS3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FADS3 RNA expression–survival associations across cancer types. High FADS3 expression shows unfavorable associations in HNSC, MESO, KIRC, UVM, LGG and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FADS3 RNA expression.
This table summarizes FADS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FADS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FADS3 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC, COAD and KIRP. The HNSC box plot shows higher FADS3 RNA expression in tumor versus normal tissue (log2 FC = +2.154, t-test p < 0.001).
This table shows molecular features associated with FADS3 in patient tissues and cancer cell lines. In patient samples, FADS3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FADS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
